Vectors Research Management’s ImmunityBio IBRX Stock Holding History

Vectors Research Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,000	Closed	-$4K	–	287
2022 Q2	$4K	Buy	+1,000	New	+$4.02K	﹤0.01%	435

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vectors Research Management's IBRX Position: Q3 2022 in Review

Vectors Research Management sold out of ImmunityBio (IBRX) in Q3 2022, closing a stake of 1,000 shares — an estimated $4K sold.

Vectors Research Management first reported a position in IBRX in Q2 2022 and held it in 1 quarter. The position peaked at $4K in Q2 2022. 126 funds tracked by Wall St. Rank hold IBRX as of Q3 2022.

Vectors Research Management reported no remaining ImmunityBio position as of Q3 2022 after selling out during the quarter.
Vectors Research Management sold 1,000 ImmunityBio shares in Q3 2022, an estimated $4K.
Vectors Research Management first reported a position in ImmunityBio in Q2 2022 and held it in 1 quarter.
Vectors Research Management's ImmunityBio position peaked at $4K in Q2 2022.
126 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2022.

Based on Vectors Research Management's 13F filing for Q3 2022, filed 8 Nov 2022.